

**PATENT**  
Attorney Docket No. UCSF-08831

**REMARKS**

The Examiner has required restriction of the claimed invention, and listed the following group classifications:


Group	Claims	Description
I	1, 6, 9, 29 & 32	carboxylated glycans, methods of making and antibody binding assays
II	23	leukocyte binding assays
III	33-35	antibodies
IV	53 & 54	hybridoma cell lines
V	55	methods of reducing leukocyte extravasation
VI	79	methods of reducing leukocyte adherence
VII	88	methods of treating inflammation
VIII	107	methods of treating cancer

Applicants hereby elect to prosecute the claims of Group I, *without traverse*. In particular Applicants hereby cancel the original claims and enter new Claims 123-150, in order to further the prosecution of the present application and Applicants' business interests, without acquiescing to the Examiner's arguments, and while reserving the right to prosecute the original, similar, or broader claims in one or more future application(s). Support for new Claims 123-143 corresponding to Group I, can be found in original Claims 1-22 and 29-32, as well as the summary of the invention. Similarly support for new Claims 144-150 corresponding to Group III, can be found in original Claims 33-41, as well as the summary of the invention. Thus the new claims do no introduce new matter.

**PATENT**  
Attorney Docket No. UCSF-08831

Upon allowance of claims of Group I, Applicants respectfully request that the Examiner rejoiner claims of Group III, which depend from or otherwise include the limitations of allowable claims of Group I. Should the Examiner believe that a telephone interview would aid in the prosecution of this application, Applicants encourage the Examiner to call the undersigned collect.

Dated: June 15, 2007

By:   
Christine A. Lekutis  
Registration No. 51,934

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
415.904.6500